Confronto
Gonadorelin vs. Melanotan II
Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.
Identità
Categoria
Ricerca (altro)
Ricerca (altro)
N. CAS
33515-09-2
121062-08-6
Peso molecolare
1182.29 g/mol
1024.18 g/mol
Emivita
0.1 h
1 h
Sequenza
pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2Meccanismo d'azione
Gonadorelin
Gonadorelin acts as an agonist at the GnRH receptor on the gonadotroph cells of the pituitary and triggers release of the gonadotropins luteinizing hormone (LH) and follicle-stimulating hormone (FSH). The temporal pattern of receptor exposure is decisive: pulsatile administration mimics the natural hypothalamic secretory rhythm and sustains LH/FSH release, whereas continuous exposure leads to receptor internalisation and desensitisation with subsequent paradoxical suppression of gonadotropins. The latter principle is exploited therapeutically by longer-acting GnRH agonists.
Melanotan II
Melanotan II binds non-selectively to all five melanocortin-receptor subtypes (MC1R-MC5R). Via MC1R in melanocytes, eumelanin synthesis is stimulated (pigmenting effect). Via MC4R and MC3R in the CNS, appetite, sexual function and blood pressure are modulated. The cyclic structure and D-amino acids increase stability compared to natural α-MSH.
Base di evidenze
Evidenza più alta
Studio sull'uomo
Studio sull'uomo
Studi
4
9
di cui sull'uomo
4
5
Effetti registrati
4
4
Contraddizioni aperte
1
1
Eventi avversi documentati
2
6
Stato legale
Voci complete
Frequently asked questions
- What is the difference between Gonadorelin and Melanotan II?
- Gonadorelin is classified as "Ricerca (altro)", while Melanotan II is classified as "Ricerca (altro)". Gonadorelin: Gonadorelin is the synthetic decapeptide with an amino-acid sequence identical to endogenous gonadotropin-releasing hormone (GnRH/LHRH). Historically approved in several countries for diagnostic testing of pituitary function and for fertility indications (pump systems). A defining feature is the opposite effect of pulsatile versus continuous administration: pulsatile stimulates, continuous leads to receptor desensitisation. Melanotan II: Cyclic hepta-peptide and non-selective melanocortin-receptor agonist. Originally researched at the University of Arizona as a sun-protection concept — never approved as a medicine. Widespread on the black market; regulatory warnings for cardiovascular and oncological risks. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Gonadorelin or Melanotan II?
- The highest available evidence level is "Studio sull'uomo" for Gonadorelin and "Studio sull'uomo" for Melanotan II. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Gonadorelin and Melanotan II in Germany and the United States?
- Germania: Gonadorelin — Su prescrizione, Melanotan II — Non approvato. Stati Uniti: Gonadorelin — Su prescrizione, Melanotan II — Non approvato. These are factual summaries with source and review date on the individual pages.